• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Elicera Therapeutics

2.44 SEK

-3.94 %

Less than 1K followers

ELIC

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-3.94 %
-22.95 %
-61.47 %
-52.03 %
-58.26 %
-59.48 %
-21.74 %
-
-59.61 %

Elicera Therapeutics AB is a clinical phase cell and gene therapy company that develops the next generation of immuno-oncology treatments. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T cells and two oncolytic viruses.

Read more
Market cap
162.84M SEK
Turnover
1.74M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Research
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
21.8.
2026

Interim report Q2'26

27.11.
2026

Interim report Q3'26

16.2.
2027

Annual report '26

Regulatory press releaseyesterday

Elicera Therapeutics: Elicera's Nomination Committee Proposes Margareth Jorvid as New Chair of the Board

Elicera Therapeutics
Regulatory press release6/3/2026, 3:01 PM

Elicera Therapeutics: Elicera publishes annual report for 2025

Elicera Therapeutics
Regulatory press release6/1/2026, 3:46 PM

Elicera Therapeutics: Elicera announces outcome of the rights issue

Elicera Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release5/25/2026, 7:10 AM

Elicera Therapeutics announces that the final reporting and final payment from the EIC Accelerator for the CARMA study have been approved

Elicera Therapeutics
Press release5/19/2026, 8:10 AM

DNB Carnegie Access: Elicera Therapeutics - Extended company presentation and Q&A

Elicera Therapeutics
Press release5/13/2026, 1:57 PM

Elicera Therapeutics' CSO takes temporary leave to undergo medical treatment - Di Yu appointed Acting CSO

Elicera Therapeutics
Regulatory press release5/11/2026, 12:16 PM

Elicera Therapeutics: Elicera publishes information document regarding the rights issue

Elicera Therapeutics
Press release4/21/2026, 6:53 PM

DNB Carnegie Access: Elicera Therapeutics: Withdrawing fair value following rights issue announcement - Correction

Elicera Therapeutics
Press release4/21/2026, 9:15 AM

DNB Carnegie Access: Elicera Therapeutics: Withdrawing fair value following rights issue announcement

Elicera Therapeutics
Regulatory press release4/21/2026, 6:31 AM

Elicera Therapeutics carries out a rights issue of approximately SEK 73 million

Elicera Therapeutics
Regulatory press release4/21/2026, 6:01 AM

Elicera Therapeutics AB (publ) Interim Report 1 January - 31 March 2026

Elicera Therapeutics
Press release3/20/2026, 7:53 AM

Elicera Therapeutics Announces Swedish Cancer Society's Senior Investigator Award to Chief Development Officer Di Yu

Elicera Therapeutics
Press release3/13/2026, 5:48 AM

DNB Carnegie Access: Elicera Therapeutics: Focused on the future of immuno-oncology

Elicera Therapeutics
Press release3/11/2026, 9:53 AM

Elicera Therapeutics receives Notice of Allowance for Japanease patent protecting the ELC-401 CAR T-cell candidate

Elicera Therapeutics
Press release3/10/2026, 8:41 AM

Elicera Therapeutics' Chief Scientific Officer Magnus Essand named Cancer Researcher of the Year 2026 by the Swedish Cancer Society (Cancerfonden)

Elicera Therapeutics
Regulatory press release3/6/2026, 7:30 AM

Elicera Therapeutics reports complete metabolic response (CMR) and well tolerated treatment in first two patients of cohort 3 in CARMA study, bringing total CMR to 6 out of 8 treated patients

Elicera Therapeutics
Press release2/27/2026, 7:30 AM

Elicera Therapeutics provides update on preclinical CAR T-cell program ELC-401 for glioblastoma: preclinical development concluded and clinical trial planning underway

Elicera Therapeutics
Press release2/18/2026, 12:57 PM

Elicera Therapeutics to present ipdated CARMA study data on March 6, 2026, at the 10th Zurich Immuno-Oncology Conference

Elicera Therapeutics
Regulatory press release2/13/2026, 7:20 AM

Elicera Therapeutics AB (publ) Year-End 1 January - 31 December 2025

Elicera Therapeutics
Press release2/11/2026, 1:32 PM

Elicera Therapeutics announces abstract acceptance at ISCT 2026 Dublin: Complete metabolic response achieved in four of six patients with iTANK-armed ELC-301 in CARMA Lymphoma Study

Elicera Therapeutics